



03-11-02

03C0

#3

EXPRESS MAIL CERTIFICATE

Date 3/7/02 Label No. EU 039139235-45

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

B.W. LEE B.W. Lee  
Name (Print) Signature

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No.: 4305/1H942-US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Jens HOLM; Henrik IPSEN; Jorgen Nedergaard LARSEN;  
and Michael Dho SPANGFORT

Serial No.: 10/001,245

Art Unit: T.B.A.

Confirmation No.:

Filed: November 15, 2001

Examiner: T.B.A.

For: NOVEL MUTANT ALLERGENS

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of  
Patents and Trademarks  
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form

PTO-1449 and copies<sup>1</sup> of the documents listed thereon.

<sup>1</sup>To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The undersigned is also enclosing herewith a copy of an International Type Search Report completed July 10, 2001 for the Danish counterpart of the present patent application (Danish National Application No. 01718/00), in which the presently disclosed references were cited. Since the Search Report is in English and utilizes conventional codes to characterize each cited reference, it is believed that the applicants in the above-identified patent application have now met the "concise explanation" requirement of 37 C.F.R. 1.98 (see MPEP § 609 A (3)).

International Application No. WO 98/43657, though not in the English language, is provided with an English translation of the Abstract. It is therefore submitted that applicants have satisfied the "concise explanation" requirement under 37 C.F.R. 1.98(3)(i) (see MPEP § 609 A (3)).

The present Information Disclosure Statement is being submitted in compliance

---

English language equivalent is cited, then none is known to the undersigned.

Serial No. 10/001,245  
Information Disclosure Statement

Docket No. 4305/1H942-US2  
Page 2

with 37 C.F.R. § 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 C.F.R. § 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge deposit Account No. 04-0100 for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: March 7, 2002



Mitchell Bernstein, Ph.D.  
Registration No. 46,550  
Agent for Applicant(s)

DARBY & DARBY  
805 Third Avenue  
New York, NY 10022  
(212) 527-7700

**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 4305/1H942-US2  
 APPLICANT: Jens HOLM, et al.

SERIAL NO: 10/001,245  
 FILING DATE: November 15, 2001  
 CONFIRMATION NO:

**U.S. PATENT DOCUMENTS**

<u>*EXAMINER</u> <u>INITIALS</u>	<u>DOCUMENT</u> <u>NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
-------------------------------------	----------------------------------	-------------	-------------	--------------	-----------------	--------------------


**FOREIGN PATENT DOCUMENTS**

<u>*EXAMINER</u> <u>INITIALS</u>	<u>DOCUMENT</u> <u>NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION</u>	
						<u>YES</u>	<u>NO</u>
1.	WO 99/47680	Sept. 23, 1999	PCT	C12N	15/29	X	
2.	WO 99/38978	Aug. 5, 1999	PCT	C12N	15/29	X	
3.	WO 98/43657	Oct. 8, 1998	PCT	A61K	38/00	(Abstract)	

**OTHER REFERENCES****(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)**

\*EXAMINER  
INITIALS

4. Ferreira, F., et al., (1998) Modulation of IgE Reactivity of Allergens by Site-Directed Mutagenesis: Potential Use of Hypoallergenic Variants for Immunotherapy, *The FASEB Journal*, 12: 231-242.
5. Punnonen, J., (2000) Molecular Breeding of Allergy Vaccines and Antiallergic Cytokines, *Int. Arch. Allergy Immunol.*, 121:173-182.
6. Spangfort, M.D., et al., (1997) Three-Dimensional Structure and Epitopes of Bet v 1, *Int. Arch. Allergy Immunol.*, 113:243-245.
7. Schweimer, K., et al., (1999) NMR Spectroscopy Reveals Common Structural Features of the Birch Pollen Allergen Bet v 1 and the Cherry Allergen Pru a 1, *Appl. Magn. Reson.*, 17:449-464.

**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 4305/1H942-US2  
APPLICANT: Jens HOLM, et al.SERIAL NO: 10/001,245  
FILING DATE: November 15, 2001  
CONFIRMATION NO:**\*EXAMINER  
INITIALS**

8. Singh, M.B., et al., (1999) Genetically Engineered Plant Allergens with Reduced Anaphylactic Activity, *Int. Arch. Allergy Immunol.*, 119:75-85.
9. Smith, A.M., et al., (1997) Localization of Antigenic Sites on Der p 2 Using Oligonucleotide-Directed Mutagenesis Targeted to Predicted Surface Residues, *Clinical and Experimental Allergy*, 27:593-599.

EXAMINER: \_\_\_\_\_ DATE CONSIDERED: \_\_\_\_\_

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.